Hypertrophic Cardiomyopathy

Comprehensive Clinical Guide: Hypertrophic Cardiomyopathy (HCM)

Hypertrophic Cardiomyopathy (HCM) represents one of the most complex and clinically significant primary myocardial diseases encountered in cardiology. Characterized by unexplained left ventricular hypertrophy (LVH) in the absence of secondary causes (such as systemic hypertension or valvular heart disease), HCM serves as a leading cause of sudden cardiac death (SCD) in young individuals and a significant source of morbidity in the aging population.

1. Introduction & Overview

HCM is a genetically heterogeneous, autosomal dominant disorder caused by mutations in genes encoding sarcomeric proteins. While traditionally viewed as a disease of the "thickened heart muscle," modern clinical perspectives define HCM as a dynamic, multisystemic condition involving myocardial disarray, interstitial fibrosis, and microvascular dysfunction.

Epidemiological Significance

• Prevalence: Estimated between 1:200 and 1:500 in the general population.
• Genetic Basis: Mutations in the MYH7 (beta-myosin heavy chain) and MYBPC3 (myosin-binding protein C) genes account for the majority of familial cases.
• Clinical Impact: HCM is the most common cause of exercise-related sudden cardiac death in athletes under age 35.

2. Pathophysiology & Technical Mechanisms

The pathophysiology of HCM is rooted in the "sarcomeric hypothesis," where abnormal proteins lead to inefficient force generation, compensatory hypertrophy, and subsequent cellular architecture disruption.

The Triad of HCM Pathophysiology

1. Myocardial Disarray: Histologically, cardiomyocytes are arranged in disorganized, "whorled" patterns, separated by varying degrees of interstitial fibrosis. This disarray creates an arrhythmogenic substrate.
2. Left Ventricular Outflow Tract (LVOT) Obstruction: In approximately 70% of symptomatic patients, the combination of septal hypertrophy and systolic anterior motion (SAM) of the mitral valve creates an obstruction, elevating intracavitary pressures and causing mitral regurgitation.
3. Diastolic Dysfunction: The hypertrophied, non-compliant LV exhibits impaired relaxation and increased passive stiffness, leading to elevated left atrial pressures and symptoms of heart failure with preserved ejection fraction (HFpEF).

Microvascular Dysfunction

Even in the absence of epicardial coronary artery disease, patients with HCM frequently experience myocardial ischemia. This is due to:
* Intramural small-vessel disease (medial hypertrophy and luminal narrowing).
* Increased wall stress and oxygen demand.
* Reduced coronary flow reserve.

3. Clinical Presentation & Staging

The clinical spectrum of HCM is vast, ranging from asymptomatic individuals identified through family screening to patients with debilitating heart failure or malignant arrhythmias.

Classic Symptomatology

• Dyspnea: Often the most common symptom, secondary to elevated diastolic pressures.
• Angina Pectoris: Occurs even in the absence of CAD due to the supply-demand mismatch.
• Syncope/Presyncope: Often post-exertional, resulting from either LVOT obstruction or transient tachyarrhythmias.
• Palpitations: Frequently linked to paroxysmal atrial fibrillation, a common complication of left atrial enlargement.

Clinical Staging Table

4. Diagnostic Evaluation

A robust diagnostic framework is essential for risk stratification and therapeutic planning.

Key Diagnostic Tests

1. Transthoracic Echocardiogram (TTE): The gold standard for initial diagnosis. Evaluates wall thickness (≥15 mm is diagnostic), LVOT gradient, and mitral valve morphology.
2. Cardiac Magnetic Resonance (CMR): Provides superior spatial resolution. Late Gadolinium Enhancement (LGE) serves as a marker for myocardial fibrosis and aids in SCD risk prediction.
3. Ambulatory ECG (Holter Monitoring): Crucial for detecting non-sustained ventricular tachycardia (NSVT), a major independent risk factor for SCD.
4. Cardiopulmonary Exercise Testing (CPET): Used to assess functional capacity (VO2 max) and unmask exertional LVOT gradients.
5. Genetic Testing: Recommended for the patient and cascade screening for first-degree relatives.

Differential Diagnosis

It is critical to distinguish HCM from "phenocopies":
* Hypertensive Heart Disease: Usually concentric hypertrophy; typically lacks the extreme septal thickness seen in HCM.
* Cardiac Amyloidosis: Exhibits increased wall thickness but characteristically low voltage on ECG and specific "apical sparing" patterns on CMR.
* Athletic Heart: Usually presents with mild hypertrophy (13–15 mm) and improved diastolic function, unlike the restrictive profile of HCM.

5. Management & Therapeutic Interventions

Therapeutic goals are centered on symptom relief and the prevention of sudden cardiac death.

Pharmacological Management

• Beta-Blockers: First-line therapy. Reduce heart rate, prolong diastolic filling, and decrease contractility to reduce LVOT gradients.
• Non-dihydropyridine Calcium Channel Blockers (Verapamil/Diltiazem): Used if beta-blockers are poorly tolerated.
• Disopyramide: A potent negative inotrope used to reduce LVOT obstruction.
• Mavacamten: A novel cardiac myosin inhibitor that directly reduces hypercontractility; the first FDA-approved disease-specific treatment for obstructive HCM.

Invasive Interventions (For refractory LVOT obstruction)

• Septal Myectomy: The "gold standard" surgical procedure. Involves the resection of the hypertrophied basal septum.
• Alcohol Septal Ablation (ASA): A catheter-based procedure injecting ethanol into the septal artery to induce a localized myocardial infarction, thinning the septum.

6. Risks, Contraindications, and Prognosis

Risks and Complications

• Sudden Cardiac Death: Primarily due to ventricular fibrillation.
• Atrial Fibrillation: Increases risk of thromboembolic stroke; necessitates chronic anticoagulation.
• Heart Failure: Progression to a dilated, thin-walled LV (end-stage HCM).

Contraindications

• Vasodilators (Nitrates/ACE inhibitors): Should be used with extreme caution in patients with significant LVOT obstruction, as they can exacerbate the gradient and induce syncope.
• Intensive Competitive Sports: Generally contraindicated in patients with high-risk features to prevent exercise-induced arrhythmias.

7. Frequently Asked Questions (FAQ)

1. Is HCM always inherited?
Most cases are, but approximately 30-40% of patients do not have a clearly identifiable mutation. De novo mutations can occur.

2. Can I live a normal life with HCM?
Yes. With proper management, regular monitoring, and lifestyle modifications, the vast majority of patients have a normal life expectancy.

3. What is the role of the ICD in HCM?
An Implantable Cardioverter-Defibrillator (ICD) is the primary prevention strategy for patients identified as "high risk" for sudden cardiac death based on specific clinical criteria.

4. Does HCM cause chest pain even if my arteries are clear?
Yes. Microvascular dysfunction and increased wall tension cause ischemia despite clear coronary arteries.

5. How often should I have an echocardiogram?
Stable patients typically undergo imaging every 1–2 years, or sooner if symptoms change.

6. Is pregnancy safe for women with HCM?
Generally, yes, but it requires specialized high-risk obstetric and cardiac management.

7. Does Mavacamten cure HCM?
Mavacamten is a disease-modifying therapy that reduces obstruction and improves symptoms, but it is not a cure for the underlying genetic mutation.

8. What is the "burned-out" phase of HCM?
This is the end-stage where the heart muscle weakens, dilates, and loses its ability to pump effectively, often requiring heart failure management or transplantation.

9. Can exercise make HCM worse?
High-intensity, competitive athletics can increase the risk of malignant arrhythmias in high-risk patients. Moderate, non-competitive exercise is usually encouraged.

10. Should my family members be tested?
Yes. Cascade screening (clinical evaluation and genetic testing) is standard protocol for all first-degree relatives of an affected individual.

Conclusion

Hypertrophic Cardiomyopathy requires a sophisticated, multidisciplinary approach. By integrating clinical, genetic, and advanced imaging data, clinicians can effectively stratify risk and provide personalized care. As we enter the era of precision medicine, the focus is shifting from merely managing symptoms to utilizing disease-modifying agents to improve long-term outcomes for those living with this condition.